Kennedy Exposes FDA’s Dangerous Double Game

Robert F Kennedy JR in suit indoors — Kennedy Exposes FDA's Dangerous Double Game

Robert F. Kennedy Jr.’s explosive claim that the FDA is reviewing the safety of the widely used abortion pill Mifepristone has reignited a firestorm.

Story Overview

Kennedy announces that the FDA is conducting a safety review of mifepristone, citing studies that show higher complication rates.
Major medical organizations defend the drug’s two-decade safety record, calling the review politically motivated.
FDA has found no new safety concerns in recent reviews, contradicting Kennedy’s claims.

Kennedy Challenges Medical Establishment on Abortion Drug Safety

On September 25, 2025, Robert F. Kennedy Jr. made headlines by announcing that the FDA was reviewing the safety profile of mifepristone, the abortion pill used by millions of women since its 2000 approval. Kennedy referenced studies suggesting serious adverse events occur in up to 11% of cases, a stark contrast to the established medical data showing rates of just 0.5%. This dramatic discrepancy raises serious questions about either the quality of Kennedy’s sources or the transparency of our regulatory agencies.

The timing of this announcement is particularly noteworthy, coming from a presidential candidate who has positioned himself as a public health advocate willing to challenge government agencies. Kennedy’s willingness to question the FDA’s oversight demonstrates the kind of accountability that has been sorely missing from our federal bureaucracy. However, the validity of his claims requires careful scrutiny given the overwhelming medical consensus supporting mifepristone’s safety record.

Kennedy says FDA is reviewing safety of abortion pill mifepristone https://t.co/EInOLcAke3

— CBSColorado (@CBSNewsColorado) September 26, 2025

Medical Organizations Push Back Against Review

The American College of Obstetricians and Gynecologists and the National Abortion Federation swiftly responded to Kennedy’s announcement, defending mifepristone as “unequivocally safe and effective.” These organizations argue that the drug’s safety has been proven through rigorous clinical evidence and two decades of post-marketing surveillance. Their defensive posture, while understandable from a medical standpoint, also reflects the deeply entrenched institutional resistance to any questioning of established protocols.

The National Abortion Federation went further, criticizing what they termed the “politicization of the review process.” This response highlights a concerning trend where legitimate safety questions are dismissed as political attacks rather than addressed through transparent scientific inquiry. When medical organizations become more focused on protecting their positions than examining evidence, it undermines public trust in both the medical establishment and regulatory oversight.

FDA’s Contradictory Position Raises Questions

The FDA’s official position creates more confusion than clarity in this controversy. While agency documentation shows no identification of new safety concerns in recent periodic reviews, Kennedy claims the agency is actively reviewing mifepristone’s safety profile. This apparent contradiction demands explanation from an agency that has consistently expanded access to the drug over its 25-year approval history, including relaxing safety protocols during the COVID-19 pandemic.

The FDA’s Risk Evaluation and Mitigation Strategy (REMS) program, established in 2011 for mifepristone, was designed to ensure safe use and manage potential complications. However, if Kennedy’s claims about higher adverse event rates have merit, it suggests either the REMS program is inadequate or that adverse events are being systematically underreported. Either scenario points to regulatory failure that demands immediate investigation and transparency.

Government Overreach Versus Public Safety

This controversy exposes the fundamental tension between government regulatory authority and individual medical decision-making. The FDA wields enormous power over drug access, yet operates with limited transparency and accountability to the American people. When conflicting safety data emerges, as Kennedy suggests, the public deserves full disclosure rather than bureaucratic stonewalling or dismissive responses from medical organizations with clear financial and ideological interests.

The broader implications extend beyond abortion policy to questions of regulatory capture and institutional accountability. Federal agencies must be held to the highest standards of scientific rigor and transparency, regardless of the political sensitivity of the drugs they regulate. Americans have the right to complete and honest information about medical treatments, especially when serious safety questions are raised by credible sources. The swamp creatures in Washington have spent decades hiding behind medical jargon and institutional authority to avoid real accountability to the people they serve.